

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Wu, <i>et al.</i>	Confirmation No.:	3434
Serial No.:	10/781,442	Art Unit:	1626
Filed:	February 18, 2004	Examiner:	Grazier, Nyeemah
For:	Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists	Attorney Docket No.:	017092-0046-999 (CAM: 011104-999015)

**CONSENT OF ASSIGNEE TO CHANGE OF INVENTORSHIP UNDER  
37 C.F.R. § 1.48 (a) AND STATEMENT UNDER 37 C.F.R. § 3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Encysive Pharmaceuticals Inc.** located at 4848 Loop Central Drive, 7th Floor Houston, Texas 77081, the Assignee of the entire right, title and interest in, to and under the invention and the above-identified U.S. patent application, filed February 18, 2004, entitled "Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists," hereby consents to the correction of inventorship in the above-identified U.S. patent application to delete inventors Eric C. Anderson, Huong Bui, Jamal Kassir, Wen Li, and Junmei Wang leaving Daxin Gao, Robert V. Market, and Chengde Wu as the inventors in said application.

**Encysive Pharmaceuticals Inc.** certifies that it is the Assignee of the entire right, title and interest in, to and under the invention of the above-identified U.S. patent application, by virtue of an assignment executed by Chengde Wu, Eric C. Anderson, Huong Bui, Daxin Gao, Jamal Kassir, Wen Li, Junmei Wang, and Robert V. Market, the presently named co-inventors of said application. The assignment was recorded on May 24, 2004 at Reel 015359, Frame 0363.

Application No. No.: 10/781,442

Filed: February 18, 2004

Page 2 of 2

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Date:

April 18, 2007

By:

Encysive Pharmaceuticals Inc.  
Paul S. Manierre

Name:

**Paul S. Manierre**

Title:

**Vice President & General Counsel**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Wu, et al.	Confirmation No.:	3434
Serial No.:	10/781,442	Art Unit:	1626
Filed:	February 18, 2004	Examiner:	Grazier, Nyeemah
For:	Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists	Attorney Docket No.:	017092-0046-999

**PETITION FOR CORRECTION OF INVENTORSHIP**  
**UNDER 37 C.F.R. § 1.48 (a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Correction of inventorship is respectfully requested under 37 C.F.R. § 1.48 (a) for the above-identified application in order to conform inventorship to the pending claims. The correct inventors of the claimed subject matter are Daxin Gao, Robert V. Market, and Chengde Wu. Thus it is respectfully requested that Eric C. Anderson, Huong Bui, Jamal Kassir, Wen Li, and Junmei Wang be deleted from named co-inventors of the above-identified application.

The requested correction is to correct an error in naming inventors that occurred without deceptive intention on the part of the above-identified persons. Statements from Eric C. Anderson, Huong Bui, Jamal Kassir, Wen Li, and Junmei Wang, the persons being deleted from the named co-inventors, that the error in inventorship occurred without deceptive intention on their part, are enclosed. Also enclosed are Declarations of Daxin Gao, Robert V. Market, and Chengde Wu under 37 C.F.R. § 1.63 and a consent by Assignee, Encysive Pharmaceuticals, Inc.

Application No. No.: 10/781,442  
Filed: February 18, 2004

A fee of \$130.00 is believed due for this submission. Should any additional fees be due for this submission or to avoid abandonment of the application, please charge such fees to Jones Day Deposit Account No. 50-3013.

Date: June 13, 2007

Respectfully submitted,



Dale L. Rieger (Reg. No. 43,045)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(212) 326-3939

*Enclosures*

# COPY

Express Mail No. EB 132601931 US  
Attorney Docket No. 017092-0046-999  
CAM 011104-999015

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Wu, et al.	Confirmation No.:	3434
Serial No.:	10/781,442	Art Unit:	1626
Filed:	February 18, 2004	Examiner:	Grazier, Nyeemah
For:	Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists	Attorney Docket No.:	017092-0046-999

### **PETITION FOR CORRECTION OF INVENTORSHIP** **UNDER 37 C.F.R. § 1.48 (a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Correction of inventorship is respectfully requested under 37 C.F.R. § 1.48 (a) for the above-identified application in order to conform inventorship to the pending claims. The correct inventors of the claimed subject matter are Daxin Gao, Robert V. Market, and Chengde Wu. Thus it is respectfully requested that Eric C. Anderson, Huong Bui, Jamal Kassir, Wen Li, and Junmei Wang be deleted from named co-inventors of the above-identified application.


The requested correction is to correct an error in naming inventors that occurred without deceptive intention on the part of the above-identified persons. Statements from Eric C. Anderson, Huong Bui, Jamal Kassir, Wen Li, and Junmei Wang, the persons being deleted from the named co-inventors, that the error in inventorship occurred without deceptive intention on their part, are enclosed. Also enclosed are Declarations of Daxin Gao, Robert V. Market, and Chengde Wu under 37 C.F.R. § 1.63 and a consent by Assignee, Encysive Pharmaceuticals, Inc.

Application No. No.: 10/781,442  
Filed: February 18, 2004

A fee of \$130.00 is believed due for this submission. Should any additional fees be due for this submission or to avoid abandonment of the application, please charge such fees to Jones Day Deposit Account No. 50-3013.

Date: June 13, 2007

Respectfully submitted,



Dale L. Rieger (Reg. No. 43,045)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(212) 326-3939

*Enclosures*